We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Hyperactive Form of IRAK4 Protein Fuels Cancerous Cells

News   Apr 23, 2019 | Original story from Cincinnati Children’s Hospital

 
Hyperactive Form of IRAK4 Protein Fuels Cancerous Cells

This image shows leukemia cells that scientists studied to identify potential treatment targets for a very aggressive form of the blood cancer, acute myeloid leukemia (AML). Researchers report in Nature Cell Biology they found a hyperactive form of a protein called IRAK4 that sends cells on a cancer-causing frenzy, which may hold a key to treating a subset of people with the disease. Credit: Cincinnati Children's

 
 
Advertisement
 

RELATED ARTICLES

mRNA COVID-19 Vaccine Is Well-Tolerated and Generates Immune Response

News

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.

READ MORE

Exploring the Landscape of Pancreatic Tumors With Single-Cell RNA Sequencing

News

A team of researchers has described the individual cells that comprise the pancreatic cancer microenvironment, a critical step in devising new treatment options for patients with this aggressive and difficult-to-treat disease.

READ MORE

The Heat Is on for Building 3D Artificial Organ Tissues

News

The labs of Kelly Stevens at the UW Medicine Institute of Stem Cell and Regenerative Medicine in Seattle and Jordan Miller at Rice University in Houston, are collaborating to develop bio-printed, organ-like tissues. Researchers would like to be able to engineer artificial tissues that could be surgically implanted to take over lost functions of diseased livers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE